CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-04 | Metzger Michael A Chief Executive Officer | Grant or award | +144,600 | 516,261 | ||
| 2026-02-04 | Metzger Michael A Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +440,000 | $20.43 | $9.0M | 440,000 |
| 2026-02-04 | Goldan Keith A. Chief Financial Officer | Grant or award | +21,500 | 115,171 | ||
| 2026-02-04 | Goldan Keith A. Chief Financial Officer | Grant or award | +30,750 | 145,921 | ||
| 2026-02-04 | Goldan Keith A. Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +118,000 | $20.43 | $2.4M | 118,000 |
| 2026-02-04 | Jarrett Jennifer Director | Grant or award | +24,000 | 114,000 | ||
| 2026-02-04 | Huber Martin H. Jr. Director | Grant or award | +24,000 | 103,000 | ||
| 2026-02-04 | Botwood Nicholas A.J. Head of R&D, CMO | Grant or award | +24,000 | 59,165 | ||
| 2026-02-04 | Botwood Nicholas A.J. Head of R&D, CMO | Grant or award | +36,000 | 95,165 | ||
| 2026-02-04 | Botwood Nicholas A.J. Head of R&D, CMO | Grant or award · Stock Options (Right to buy) | +144,700 | $20.43 | $3.0M | 144,700 |
| 2026-02-04 | Podlesak Dennis Director | Grant or award | +48,000 | 239,763 | ||
| 2026-02-04 | Rizo Aleksandra Director | Grant or award | +24,000 | 49,000 | ||
| 2026-02-04 | Katkin Keith Director | Grant or award | +24,000 | 124,000 | ||
| 2026-02-04 | Legault Pierre Director | Grant or award | +24,000 | 114,000 | ||
| 2026-01-30 | Goldan Keith A. Chief Financial Officer | Other acquisition | +1,219 | $8.48 | $10K | 93,671 |
| 2025-12-01 | Goldan Keith A. Chief Financial Officer | Gift | −1,224 | 92,452 | ||
| 2025-09-08 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 | +157,307 | $10.90 | $1.7M | 455,968 |
| 2025-09-08 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −157,307 | $16.41 | $2.6M | 298,661 |
| 2025-09-08 | Metzger Michael A Chief Executive Officer | Option exercise · Stock options (Right to buy) 10b5-1 | +157,307 | 0 | ||
| 2025-08-18 | Podlesak Dennis Director | Option exercise 10b5-1 | +19,200 | $7.20 | $138K | 210,963 |
Page 2 of 15 · 290 trades